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Abstract
Staphylococcus aureus is an emerging pathogen from dairy animals’ mammary glands. 
Among various risk factors associated with this pathogen are unhygienic milking proce-
dures, improper preventive techniques, and lack of germicidal teat dipping before and after 
milking. Methicillin-resistant S. aureus, coagulase positive S. aureus, vancomycin-resistant 
S. aureus, and biofilm-producing S. aureus are common strains of S. aureus being isolated 
from dairy milk these days. They have huge economic and public health concerns. Trials 
of antibiotic susceptibility proposed variable responses, while drug modulation and drug 
synergistic proved to be hope for its treatment. Some of the plant derivative, phages, and 
nanoparticles are non-antibiotic sources to treat S. aureus. Various attempts to treat S. aureus 
at the world level have been carried out but require more researches to be undertaken in 
order to prevent it. The chapter concludes that S. aureus from dairy needs equal attention as 
is given to S. aureus from the human origin, and researches are required to probe solutions.
Keywords: Staphylococcus aureus, prevalence, public health, antibiotic susceptibility, 
prevention strategies
1. Introduction
Staphylococcus aureus is a Gram-positive coccus, non-motile, non-spore-forming, catalase 
positive, coagulase positive, and facultative anaerobic bacteria that is responsible for all 
kinds of mastitis in dairy animals. The pathogen has developed the capability to resist action 
of most of the antibiotics used in disease management. The inflammation in mammary 
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glands of dairy animals is a worldwide issue, origin of which may be infectious or non-
infectious. The latter is less frequent that, however, occurs due to physical insult to mam-
mary glands during or after milking. The bacterial contaminants cover most of the part of 
the infectious causes of mastitis. The pathogenic pattern of S. aureus involves adherence to 
mammary epithelial cells and to the extracellular components. Subsequent to this comes 
the mammary epithelial invasion where they remain in membrane-bound vacuoles of the 
mammary gland’s epithelial cells. The phagocytic activity of the phagosome is bypassed 
to induce apoptosis. The recurrent subclinical infections occur because of bacteria dwell-
ing in epithelial cells in that they inflict injury there by the endocytic process. Not only are 
the economic and health challenges limited to bovine, but potential zoonosis exists due to 
S. aureus. A clonal complex 398 representative of livestock-associated methicillin-resistant 
Staphylococcus aureus (MRSA) has proven the ability of colonization and serious health 
consequences in humans who are in close contact with animals.
2. Prevalence of Staphylococcus aureus from dairy milk
2.1. Cattle and buffalo milk
Bovine mastitis has been reported with more than 140 bacterial species in addition to minor 
prevalence owned by fungi, algae, and virus where S. aureus stands in an average number as 
the first causative agent for this malady. S. aureus prevalence is variable, starting from less than 
10% to as high as 65%. The staphylococcal isolates from the bovine subclinical mastitis have 
been tuned to 85% in Pakistan. Recent studies in Canada reported a 46% S. aureus prevalence at 
herd level. The pathogen is invariably present in both buffalo and cattle but some of the studies 
report higher prevalence in buffalo than cattle. Variation in prevalence of Staphylococcus aureus 
within and among different dairy species might be because of bacterial survival in keratin layer 
of mammary glands where various immune evasive techniques like biofilm production are the 
reasons for lower shedding of bacteria from the mammary gland’s environment. Other fac-
tors include geographic area variation, breed, specie, and farm management. The prevalence 
of mastitis in buffalo is higher than that of cattle in various studies. The fact behind might be 
higher nutritive values of its milk that favor growth of bacteria. The longer teats with pendu-
lous shape also support bacterial invasion which is comparatively higher than that of cattle [1]. 
Some of salient features for spread of this pathogen are regarded as Milker’s hands, flies, and 
towels spread these pathogenic bacteria to clean udders during milking practices.
2.2. Camel milk
Studies about camel diseases reported lower prevalence of mastitis before the twentieth cen-
tury. The reason for not prioritizing camel mastitis was that higher contents of lactoferrin are 
recognized as antibacterial. However, later studies identified various aspects of mastitis. The 
studies on the microbial involvement find S. aureus invariably present with various percent-
ages. Its prevalence has been noted as lowest as 1.8% in Saudi Arabia and as high as 83% from 
Kenya. Pakistan has reported 74.04% of S. aureus prevalence in the camel community from 
the desert. The majority of studies reported a non-comparable higher prevalence of S. aureus. 
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However, some of the studies report it to be second major pathogen after Streptococcus 
 agalactiae, thus, meaning that the prevalence of this pathogen was noted to be 20.35% at the 
world camel community so far. Variation in prevalence has been attributed to the irregular 
shedding pattern of this bacteria, different hygienic standards at farms, unhygienic milking 
process, and lower than required inoculum (0.1 mL) for streaking on growth media and bio-
film production. Unhygienic conditions are dominant in the desert environment which results 
in heifer-harboring intra-mammary bacteria that upon giving birth keep shedding in milk. 
Use of devices to stop calf suckling, tick infestation, udder deformities inflicted by thorny 
bushes, and camel pox favors the spread of mastitis. All these factors are unleashing S. aureus 
incidences. Some diagnostic screening techniques have been attempted for early identification 
of this pathogen that otherwise requires biochemical protocols. Sensitivity of the California 
mastitis test is reported to be 68% in a study. In case of camel milk, the California mastitis test 
is difficult to perform in that large numbers of cellular fragments surrounded by plasma mem-
brane having rough endoplasmic reticulum and mitochondria but lacking nucleus are found 
normally in milk. Presence of these cellular fragments creates false positive results that nor-
mally require lymphocyte, neutrophils, and macrophages that are markers of inflammation.
2.3. Goat milk and sheep milk
S. aureus prevalence in caprine milk has been tuned to 66% [2]. Raw milk cheese and unpas-
teurized milk is consumed on traditional grounds. Apart from quality and quantity of milk 
deterioration, bulk milk contamination with S. aureus reflects the severity of farm’s subclinical 
and clinical mastitis. This could be a reason of high observation of S. aureus from bulk milk. 
Swiss dairy farms reported 30% of goat and sheep herds having been identified with S. aureus. 
The virulence of S. aureus observed was same both for caprine and for ovine in terms of splE 
and sdrD. Higher prevalence of spLE was observed in goat milk while lukM was observed in 
sheep milk. Genes that code superantigen-like proteins (ssl) were observed to be immunoeva-
sive as they interfere the toll-like receptor system. The biofilm-forming gene (Q7A4X2) was 
observed in addition to sdrD, splE, and lukM that are mainly virulent factors of S. aureus iso-
lated from small ruminants. Studies have reported that the Staphaurex latex agglutination test 
is a more effective diagnostic tool in case of caprine and ovine S. aureus. This test was reported 
to present 51% of results as false negative when used as a diagnostic test for bovine S. aureus. 
Information is limited on raw bulk milk contamination with S. aureus. There are limited studies 
reporting ewe’s bulk milk tank contamination with Staphylococcus aureus. The heterogeneity in 
S. aureus reporting exists with peak percentage during the 2003 studies that reports 33.3% [3, 
4]. However, meat of ewes is reported to have 20–94% of S. aureus incidences [5].
2.4. Risk factors
The animals in older age are more prone to mammary gland infection due to dilated teats, 
previous repeated exposure to infection, and lower immune response [6]. The animals in old 
age are at double the risk with mastitis than animals of younger age. On the other hand, some 
of the studies did not find age as a risk factor for mastitis. The unhygienic conditions at farms 
along with other risk factors may result in infection to animals irrespective of age. Lactating 
animals are more prone to Staphylococcal infection because at lactation state spread of con-
tagious pathogen increases if hygienic measures are not adopted. The periparturition period 
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is most susceptible to disease because of lower immune response during this period. Some of 
the studies report higher prevalence of disease in late lactation with reasons of lower immune 
response [7]. Early lactation was also found susceptible in some of the studies with reasons 
of higher milk production which is positively correlated with spread of mastitis. Ticks work 
to spread the pathogen from one animal to other. They create a suitable environment to aid 
microbial pathogenesis. Most of the studies have reported higher prevalence of mastitis in 
cases where ticks were infecting.
The higher parity was found more susceptible to infection. This was justifiable with carryover 
of infection from one parity to the next. Some of the researchers did not find the correlation 
of mastitis with parity number [8]. S. aureus being contagious is positively correlated with an 
unhygienic milking system. Fore milking stripping is found with S. aureus that may spread 
to other animals if hygiene is not adopted [9]. While conducting studies on prevalence of S. 
aureus, it is advised to discard the first few strippings of milk. However, spread of environ-
mental mastitogens is not linked with fore milking stripping. The farms where teat dipping 
before and after milking with chlorhexidine and iodine is being practiced are reported to have 
reduced chances of disease [10]. They are discovering alter resistance of antibiotics against 
foodborne bacteria [11].
2.5. Types of S. aureus strains isolated from dairy milk
Staphylococcus aureus comes from the family Staphylococcaceae and genus Staphylococcus. The 
Staphylococcus genera is reported to have 42 species that are further categorized based on coagu-
lase production. There are some of species of this genus that are normal inhabitants of the skin 
and mucus membrane. The species other than Staphylococcus aureus that produce coagulase 
and are found in etiologies of mastitis include Staphylococcus intermedius and Staphylococcus 
hyicus. The production of coagulase may not be strictly adherent to these strains due to advent 
of genetic variation. In addition to this phenotypic identification, results’ interpretations exist 
[12]. This invites nucleic acid target-based techniques for the sake of identification and clas-
sification. The virulent genes namely spa igG binding, icaA, icaD, agrI-agrIII, cap. fnbA, fnB, 
hla, hlb, clfA, nuc, and spa X-region are linked to bovine mastitis. Added to these are mecA 
gene, blaZ gene, vancomycin-resistant genes, and hyper-virulent genes that increase diagnos-
tic labor [13]. Salient virulence factors that include hemolysin (alpha, beta, gamma, delta), 
heat-shock protein, enzymes (nuclease, lipases, protease, staphylokinase, esterase), capsular 
polysaccharides, slime, cell-adhered proteins (fibronectin-binding protein, elastin-binding 
protein, collagen binding protein, and protein A) have been frequently identified from dairy 
milk. They have direct effects on public health (14, 13). Methicillin-resistant S. aureus not only 
spreads to animals but also has been reported to develop outbreak in humans [14].
Biofilm-producing strains in subclinical and clinical mastitis are also one the rise. These are 
sessile microbial-derived community of cells that get attached to substrate or to the each other 
whereby they are embedded in self-produced extracellular polymeric substance of diverse con-
stituents like DNA, protein, carbohydrate and so on [15]. Identification of these strains from S. 
aureus has been tuned to 61%, and this may increase in environment where suitable risk factors 
are observed. The intra-mammary infections settled for long periods call for adhesive colonies’ 
aggregation that are surrounded by the self-created exopolysaccharide matrix, the biofilm. The 
biofilms evade phagocytosis because of higher size. The matrix of biofilm varies from specie to 
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specie, and also the environmental circumstances play a role in determining the complexity of 
the biofilm’s matrix. Biofilms have proven resistance to ultraviolet light, antibacterial drugs, bio-
cides, biodegradability, and amplified genomic diversity, diversified degradability, and higher 
production of secondary metabolites [16]. The resistance to antibiotics is attributed to the physi-
cal barrier (exopolysaccharide), limited growth of bacteria in biofilm, accumulation of antibi-
otic-degrading enzymes in the matrix, and transformation of protein in the cell wall of bacteria.
2.6. Public health concern
Staphylococcal food poisoning (SFP) cases have been reported by Centers for Disease Control 
(CDCs) in the USA to be as high as 240,000 [17], while Europe observed 386 outbreaks in 
2014 (Anonymous, 2015). The outbreaks are characterized with diarrhea and violent vomiting 
soon after ingesting SFP food. Analysis realized the involvement of enterotoxins and super 
antigens; some of those were classical enterotoxins like SEA-SEE and others were newly iden-
tified [18]. The necessitation of identification of S. aureus from domestic animals is impartial 
because of their residency in animals that act as a reservoir for onward infection. The fea-
ture is in addition to their role in compromised livestock economy [19]. The spread to public 
health presented new strains entitled LA-MRSA (livestock-associated methicillin-resistant 
Staphylococcus aureus). The frequent isolation of LA-MRSA has been observed by farmers, vet-
erinarians, and farm workers’ family members [20]. S. aureus produces heat-resistant entero-
toxins that are one of the leading food poisoning causes. They are actually of 26900–29600 
Da, molecular weight moiety, that up till the moment is nearly 20 different kinds of isolated 
entitled as staphylococcal enterotoxins (SE) and staphylococcal enterotoxin-like proteins 
(SEI). The prevalence of enterotoxins is rising in various dairies. These enterotoxins may be 
effective in milk even when S. aureus is not viable [21]. In Turkey, 46.9% of SEs of one or more 
types were isolated from subclinical bovine mastitis [22]. The Samsun province of Turkey pre-
sented 75% enterotoxins from raw milk [23], while 68.4% of strains isolated from bovine raw 
and pasteurized milk were positive for SE genes. The toxic proteins of bacteria exploit host 
tissues to produce nutrients for their growth. Staphylococcal enterotoxins are hypothesized 
to induce emesis. They are associated with inflammatory mediators like prostaglandin E
2
, 
5-hydroxyeicosatetraenoic acid, and leukotriene B4. The observed areas of inflammation in 
gastrointestinal tract appear with upper part involving stomach and intestine. The observable 
pathogenesis includes exudate in duodenum.
Not only had the raw but processed milk also reflected 10.4% of S. aureus prevalence, the 
analysis isolated five virulent genes encoding Paton-Valentine leukocidin, staphylococcal 
enterotoxin, toxic-shock syndrome toxin-1, methicillin resistance, and exfoliative toxin. 
More than 60% of strains presented greater than one virulent factor. The strains show vari-
able response to various classes of antibiotics and even to the members of each class. Cheese 
made of goat milk may have this pathogen as some of the studies have detected 9.5% of this 
pathogen’s involvement that was characteristically enterotoxigenic, coagulase positive, and 
methicillin resistant. The studies found six new alleles (glpf-500, pta-440, aroe-552, aroe-553, 
yqil-482, and yqil-496) and five newer sequence types (STs) that is to say ST 3431, ST 3440, 
ST 3444, ST 3445, and ST 3461 in S. aureus from goat milk. Isolation of novel alleles in Staph 
areus from goat is thought normal than those of bovine and humans in that more focused 
studies are scarce in case of goats.
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2.7. Economic damages
Economic damages that are outcomes of clinical and subclinical mastitis are entitled as reduced 
milk yield, spoiled milk, lower milk quality, unstable taste, reduced milk processing, lower 
shelf life, and decreased yield of milk products. The ancillary economic burden includes treat-
ment costs, spread of disease, culling, veterinarian fee, and labor costs. For staphylococci, losses 
to dairy in the Dutch dairy system were noted to be €293 per cow clinical mastitis. Dairy cattle 
per cow clinical cases were anchored to estimated €277 for the first three month’s post-calving 
and €168 onward to the end of lactation. In US dairy circumstances, the estimated economic 
damages in dollars are estimated to be $1.8 billion/9 million dairy cows on an annual basis, 
exclusive of antibiotic residual in human diet, costs used to control milk’s nutritive quality, and 
degradation of milk.
2.8. Drug susceptibilities and drug modulation
2.8.1. Susceptibility
The susceptibility of S. aureus from bovine mastitis is variable in the increase or decrease in 
resistance against antibiotics. Somewhere, S. aureus is noted to be pan-susceptible to antibiotics 
in studies from goats, while pan-resistance from bovine milk is also on record. The report of a 
retrospective study concludes two times the reduction of S. aureus resistance against penicillin 
while six times resistance against erythromycin over a period of 6 years [24]. This was not true 
in reports encompassing results of studies conducted in other geographical locations where 
resistance to the antibacterial drug increased to double of what was reported 12 years ago [1, 
25]. The studies later to 2001, however, mention increase in general resistance of S. aureus strains 
against antibiotics. The difference in trends is attributed to evolution of resistance against local 
microflora being under therapy selection, traditions of farmers, drug regulation of country, 
local antibiotic therapy protocols, and number of processed samples in the study. Bacteria use 
horizontal gene transfer from resistant to sensitive strains [26]. The prevalent resistance genes 
noted in S. aureus encode for oxacillin (mecA), erythromycin (ermA, ermB, erm C), gentamicin 
(aac-6/aph-2), and tetracycline (tetK and tetM), penicillin (blaZ), and vancomycin [27].
Penicillin and cephalosporin group of antibiotics are found to be generally resistant against 
Staphylococcus aureus from bovine and camel milk. However, susceptibility varies from species 
to specie, region to region, strains of Staphylococcus aureus, and frequent exposure to antibi-
otics. Cefoxitin- and vancomycin-resistant strains are emerging. Linezolid is however effec-
tive in current dates against Staphylococcus aureus strains of bovine milk. The antibiotic trials 
have presented ciprofloxacin, gentamicin, trimethoprim-sulfamethoxazole, chlorampheni-
col and tetracycline effective against Staphylococcus aureus that originates from various dairy 
animals. Higher susceptibility of S. aureus could be because of infrequent use of antibiotics 
in that area. Pan-susceptibility is noted higher than all dairy animals in that the drugs that 
usually face resistance by S. aureus of other dairy animals are quite effective in case of ovine 
S. aureus. Penicillin resistance is extensively noted while limited resistance was found when 
tested against S. aureus of ovine milk. The current status of ovine-based S. aureus was 100% 
susceptible at Greece farms, which thus reflects an absence of methicillin-resistant strains. The 
feature is attributed to very low pressure of antibiotic use at sheep farms in Greece. Traditional 
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farming is mostly on organic farming so they are safe from MRSA infection that in turn draws 
attention toward ovine milk as safe food.
2.8.2. Drug combinations
The increased resistance has been noted against all kinds of antimicrobials and no introduction 
of any new drugs has invited the use of newer drug combinations. Some of the drugs from the 
aminoglycoside group are although effective but reportedly linked to ototoxic and nephrotoxic 
effects due to their continued use. The drug combination requires antibiotics to target at dif-
ferent sites. Penicillin group in conjunction with aminoglycoside was reported as potent, effec-
tive, and safe. Combination of cephalosporin (cefaroxil) and penicillin (amoxicillin) showed 
synergistic effects against 80% of resistant isolates. Within the drug class, for example, β-lactam 
with ß-lactam combinations, efficient results were presented as well [28], and in vivo trials 
have also proved their effectiveness. Aminoglycosides are potent drugs that create fissures in 
the outer portion of bacterial cell wall by binding with 30S ribosomal subunit, thus misreading 
mRNA. Penicillin in combination with chloramphenicol has been reported synergistic in some 
of the studies while antagonistic results have also been reported. Antagonism reported in some 
studies claim penicillin to activate while chloramphenicol to deactivate murein hydrolase that 
in its function is responsible for lysis of bacteria. The general concept describes bactericidal and 
bacteriostatic to be antagonistic which is now true in other studies [29]. This trend might be 
because of diversification of genetic variation in modern pathogens.
2.8.3. Plant derivative effects/drug modulation
Plants have various antimicrobial peptides like c-thionin and thionin Thi 2.1 tested against 
intracellular S. aureus of bovine mastitis. These peptides in addition to their antibacterial activ-
ity work as immune modulators. The extracts from other plants like ethanolic extract of propo-
lis (EEP), a resinous mixture obtained by honeybees from plants, are reported to be highly 
biologically active against S. aureus mastitis. There is limitation attached with this in terms of 
lower minimum inhibitory concentration (MIC) when tested in milk environment. However, 
authors have suggested its in vivo activity against mastitis. Monolaurin, a coconut oil deriva-
tive made of glycerol monoester of lauric acid, has also presented antibacterial activity against 
S. aureus. Extracts of Tabernaemontana divaricata (L.) have shown significant efficacy against 
a group of microorganisms of bovine mastitis origin which demand further research to be 
undertaken [30]. The bovine clinical mastitis-based S. aureus showed sensitivity against crude 
extracts of Combertum molle and Commicarpus pedenculosus medicinal plants [7].
The development of resistance demands some alternative ways to combat S. aureus. The bac-
terial resistance takes place due to impairment in binding as a consequence of genetic muta-
tions, enzyme production, for example, hydrolyzing that impaired amide bond, and efflux 
extrusion which is responsible for reduction in drug concentration inside the cell [31, 32]. 
The constituents of plant extracts modulate resistant mechanism techniques of bacteria to the 
extent where they become sensitive. Various in vitro trials have been reported with promising 
results against multidrug-resistant S. aureus. Some of the plants naturally growing in animal-
rearing areas are featured with antimicrobial characteristics. A few among 500 plant species 
are explored in documentation with proven antibacterial effects. There is wider scope yet to 
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be explored as an alternative source of bactericidal. Calotropis procera and Eucalyptus globolus 
have proven activity against S. aureus. These plants are salt and drought resistant growing 
in wider quantities in the surroundings of animal-rearing far areas. Plant extracts in synergy 
with antibacterial drugs target various sites of S. aureus, thus modifying phenotypic resistance 
to sensitivity [33]. The antibacterial activity is attributed to flavonoids, alkaloids, saponins, 
glycosides, phenols, and tannins. The active ingredient gives rise to the porous cell wall, thus 
releasing contents from cytoplasm, electron-transport chain inhibition, and interference with 
sphingolipid inhibition [34]. The activity may vary depending on the variation in solvents 
for extraction, the stage of plant’s cultivation, geographical area, method of extraction, and 
specific mode of action [32].
2.8.4. Nanoparticles
The recent few years have presented nanoparticles (NPs) which have emerged as a cost-
effective potential antibacterial against various pathogens. Nanoparticles (NPs) are small par-
ticles of 1–100 mm size and work by disruption of cell membrane, simultaneous activation 
of multiple mechanisms, and action as antibiotic carriers. They break physical barriers made 
of biofilms to reach bacterial cells embedded inside whereby antibiotics cannot reach alone. 
Oxidative stress, non-oxidative stress, and metal-ion release mechanisms are used by Ag, Mg, 
NO, ZnO, CuO, Cu
2
O, Fe
2
O
3,
 FeO, and many others to kill bacteria. Multiple drug-resistant 
S. aureus showed a 177 mm zone of inhibition at 80 𝜇L of silver nanoparticles. Nitric oxide 
nanoparticles are not only effective against S. aureus but also play a role in prevention of mas-
titis in dairy animals. They alone and in combination with antibiotic preparation are evalu-
ated in vitro targeting S. aureus and also the wound healing. Nanoparticles that work as drug 
delivery include liposomal NPs, inorganic NPs, polymer-based NPs, terpenoid-based NPs, 
and polymer micelle NPs. These nanoparticles coat antibiotics and effectively reach to the site 
where the drug mechanism does not work. The encapsulation of antibiotics with nanopar-
ticles makes drugs express their potential that in alone are unable to impart their effect. 
Tilmicosin-solid lipid and amoxicillin are sometimes unable to deliver their effects alone but 
encapsulation with nanoparticles complements their activity at full bloom. Hydrogel-coated 
nanoparticles, for example, sliver hydrogel coated, proved to be superior in antibacterial 
activity, viscosity, and drug release. Several studies have proven their efficacy in terms of 
wound healing, normal skin appearance, and hair growth. These particles help make produc-
tion of hydrogen per oxide and reactive oxygen species at wound site that help cure infection/
mastitis. The small-size particles confer cell death and reduction of bacterial resistance.
2.8.5. Other alternatives
Phages are alternative sources where no other therapeutic action against pathogens is work-
able. The staphylococcal species may effectively be lysed with phage K. Moreover, phage K 
can be used prophylactically against intra-mammary infections endorsed by S. aureus. Phage 
K is reported as a pocket rocket against mastitis by some researchers. On the other hands, 
phages are vulnerable to mammary glands’ immune system and whey protein of milk that 
render phages ineffective [35]. Studies are needed to rule out pharmacokinetics and pharmaco-
dynamics in addition to the challenges of their administration into tissues. Another polyvalent 
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virulent phage, MSA6, is isolated from cow mastitis that is being used as a potential universal 
anti-staphylococcal agent [36]. This particular phage is applicable against a wider host range, 
superior lytic action, and importantly are thermo stable. The peptidase derived from the bac-
teriophage, CHAP
K
, of cow mastitis is effective both at prophylactic and at therapeutic ends. 
Biofilm-producing strains of S. aureus may be effectively prevented from biofilm production 
and disruption of already established biofilms. Stress can affect bacteriophage activity. Some 
bacteriophages including Sabp-P1, Sabp-P2, and Sabp-P3 are resistant to environmental stress 
[13]. Apart from limitations, phages resistant to stress can be best applicable for futuristic 
staphylococcal mastitis treatment.
Cytokines are proteins with a definitive role in cell signaling. Some of the recombinant cytokines 
of bovine origin like IL-2, IFn-c, and TNF-alpha stimulate both kinds of immunity (innate and 
acquired) in mammary glands. However, their effect in combination with antibiotic therapy is 
additive against mastitis [37]. Beta-lactoglobulin protein is normally present in mammal’s whey 
while lactoferrin is present in milk, bronchial mucus, saliva, and tears. Both molecules have 
proven activity against S. aureus-based mastitis. These proteins complement a higher spectrum 
of antimicrobial activity either applied alone, in combination with each other, or in combina-
tion with antibiotics. There are other animal-derived sources like marine sponges that exhibit 
antibacterial activity against a wider range of Staphylococcal species when used in extracts. 
These sponges include species from Cinachyrella, Haliclona, and Petromica that were effective 
antimicrobial agents against 61% of tested microorganisms [38].
2.8.6. Bacteria with probiotics
Mechanisms of persistence of S. aureus in intra-mammary environments still need to be 
explored but evasion of host immune system and adherence to epithelial cells of mammary 
glands are some of the known in this regard [39]. Some bacteria like Weisella confuse and 
Lactobacillus casei are reported to produce certain compounds that are active against internal-
ized persistence of S. aureus. Lactic acid bacteria have the ability of adherence to epithelial 
cells, thus resisting S. aureus pathogenicity by its competitive adhesion ability, production of 
H
2
O
2
 , competition in nutrition utilization, and host immune modulation [40]. Continuous use 
of Weissella strains and their metabolites are reported to be effective alternatives of antibiotics 
in control and prevention of mastitis [41].
2.9. Prevention strategies against dairy S. aureus
Controlling S. aureus in dairy products is needful for commercial and profitable small-scale 
cow farming for improving milk quality to consumers as well as dairy industries. Although a 
significant progress has been done in over the last 30 years, S. aureus seems to be still severe in 
dairy animals around the world. The lack of effectiveness of the current strategies (principally 
based on antiseptic teat dipping after milking and antibiotic therapy during the dry period) to 
suppress S. aureus has promoted in the sense of vaccine preparation against S. aureus which is a 
reasonable/alternative approach for the control of these microorganisms associated with mas-
titis. Studies have reported higher prevalence coupled with increased resistance to antibiotics 
in S. aureus isolates of camel mastitis [42, 43]. The emergence of discrepancies in resistance 
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identification has also added to increased resistance in terms of unjustified use of antibiot-
ics to combat S. aureus [44, 45]. Resistance to antibiotics and the phagocytosis phenomenon 
leads to treatment failure against S. aureus, so the vaccine development against mastitis is an 
exigent to prevent new infections by S. aureus for commercial dairy farms. Anti-Staphylococcus 
aureus vaccines give different results, depending on the type of vaccine, the adjuvant used, 
and some other factors involved.
2.9.1. Vaccinal targets in S. aureus
Several studies have shown that different soluble and cytotoxic factors are involved which 
increase the S. aureus pathogenicity by using different pathogenic factors, for example, pseudo-
capsules, toxins, clumping factors, protein A, and fibronectin-binding protein. It has been sug-
gested that these pathogenic factors should be considered for preparing mastitis vaccine to be 
used in field conditions. Furthermore, it has recently been suggested that the S. aureus vaccine 
may be much effective if it is multicomponent integrated with surface proteins, toxins, and 
surface polysaccharides. Recently, it has been proposed that more than 99% of the world’s 
bacteria exist as biofilm producers. Experts at disease control and prevention centers, the USA, 
estimate that 65% of human bacterial infections are involved in biofilm production [46]. The 
term “biofilm” for bacteria refers to a structured population of bacterial cells enclosed in a self-
produced polymeric matrix and attached to an inert or living surface that forms a protected 
growth pattern that allows surviving in harsh environments. Biofilm-forming microorganisms 
produce a particular mechanism to attach the surface to form a microbial community, produc-
ing a three-dimensional structure of mature biofilms [47]. Their growth rate, composition, and 
resistance to anti-biocides, antibiotics, and antibodies are all different because they up-regulate 
and/or down-regulate about 40% of the genes. This makes it difficult to eliminate the infections 
due to such microorganisms with therapeutic doses of antimicrobials. A better understanding 
of the mechanisms by which they can evolve and survive in sessile environments can help in 
designing control strategies against S. aureus [48].
2.9.2. Vaccines in action
There is growing evidence that S. aureus can form biofilms in the udder of dairy cows affected 
by mastitis. Biofilms not only affect the host’s immune system but also prevent the action of 
antibacterial drugs, leading to persistent infection. S. aureus causes chronic infections, result-
ing in significant financial losses in most of the cases [49]. Biofilm is an important factor in 
the virulence of S. aureus [50]. It has been demonstrated that the active immunization of exo-
polysaccharides extracted with strongly adherent S. aureus isolates provokes the defensive 
immunity against mastitis [51]. The use of antibiotics to treat and prevent Staphylococcus aureus 
mastitis has driven mastitis researchers in preventing udder infections through vaccine due to 
high costs, low cure rates, high antibiotic resistance, and consumer concerns about antibiotic 
residues in milk and meat [52]. Various mastitis vaccines have been studied including inac-
tivated whole cell, live vaccines, cell wall components, bacterin toxoid, and antigen extracts 
with or without adjuvants. Findings of some researchers are summarized later. Israeli workers 
[53] supervised a large number of field trials with commercially available vaccine (MSTIVAC 
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I; Patent No. PTC/IL 98/00627) for S. aureus mastitis. The authors observed a 42–54% reduction 
in first and second lactation in SCCs and 0.5 Kg/day/animal increase in milk production as 
compared to unvaccinated (control) cows. In the vaccinated group, only 3 out of 228 animals 
(1.3%) while in the control group 6 out of 224 (2.7%) was detected. No statistical analysis was 
conducted as these numbers were low for statistical analysis between vaccinated animals and 
non-vaccinated (control) animals. Later on, findings of Athar [54] at the Department of Clinical 
Medicine and Surgery of the University of Agricultural Faisalabad (UAF), Pakistan, confirmed 
that the locally developed polyvalent vaccine for mastitis (incorporated with killed S. aureus, 
S. agalactiae and various E. coli) provided protection for new infections as well as eliminated 
existing infections in dairy buffaloes. Similarly, other authors have also observed such findings 
with locally prepared S. aureus vaccines (plain bacterin, oil-adjuvant bacterin, live attenuated 
vaccine and dextran sulfate-adjuvant bacterin) [47]. Brouillette et al. [55] conducted a DNA 
immunization study against the Staphylococcus aureus aggregation factor A (CIF-A). It has been 
found that preincubation of S. aureus with serum obtained from vaccinated mice reduces the 
ability of pathogens to bind up to 92% of fibrinogen. These preincubated bacteria were phago-
cytosed by elevated macrophages in vitro, whereas, in in vivo trials, these were less toxic when 
evaluated experimentally in a mouse-mastitis model. However, DNA-immunized mice could 
not resist the challenges caused by the intraperitoneal route. The results showed that DNA 
immunization can be used as a new method to prevent S. aureus infection.
2.9.3. Current scenario of vaccines
In this new era, mastitis has been one of the imperative diseases in dairy cows, despite tremen-
dous advances in improving overall udder health. Epidemiological studies have showed a lot 
of variations in biological cure rates (from 0 to 80%) following antibiotic treatment, but these 
do not show the significant loss of antibiotic activity of the major classes. Repeated infections 
often lead to the formation of biofilms in bacteria. In the case of microorganisms, biofilm for-
mation is caused by subsequent physiological and significant genetic changes resulting in loss 
of sensitivity to antibiotics, thus leading to development of resistance to antibiotics of different 
classes. Ahmad and Muhammad [56] conducted a study on the preparation and evaluation 
of S. aureus and S. agalactiae aluminum hydroxide adjuvant mastitis vaccine in rabbits. Bio-
characterization of both bacteria was done from 95 milk samples collected aseptically from 
mastitic buffalos. Immunogenicity, pathogenicity and susceptibility testing of antibiotics was 
performed. Bivalent aluminum hydroxide adjuvant vaccine was developed in the Mastitis 
Research Laboratory at Clinical Medicine and Surgery Department, University of Agriculture 
Faisalabad-Pakistan. The vaccine was proved stable, sterile, and safe to use. Rabbits were used 
to evaluate the quality of the vaccine and the antibody response. For this purpose, rabbits were 
divided into two (GA and GB) groups, having 10 rabbits in each. Rabbits in the GA group 
were injected with S. aureus and S. agalactiae aluminum hydroxide-adjuvant mastitis vaccine, 
while the rabbits in second group (GB) remained non-vaccinated. To check the antibody titers 
in rabbits of group GA, indirect hemagglutination inhibition assay (IHA) was performed. GA 
rabbits had the highest anti-S. aureus serum antibody titer (GMT) which was 78.8 at the 45th 
day, dropping slightly to 73.3 on day 60 post-vaccination. IHA titer gradually increased for 
S. agalactiae at days 45 and 60 after the inoculation of vaccine. The cumulative mean antibody 
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titer (CMT) for the vaccinal S. aureus was 44.94 and CMT for the vaccinal S. agalactiae was 
46.56 as compared to the control group. The CMT was significantly higher in vaccinated group 
at days 45 and 60 after the vaccination than the control group. The study showed that the 
bivalent aluminum hydroxide-adjuvant vaccine was immunogenic in rabbits. To evaluate the 
S. aureus bacterin, Middleton [57] used a lactating cow model to study the ability of this vac-
cine to prevent intra-mammary infections (IMI) of staphylococcal (S. aureus and coagulase-
negative staphylococci (CNS)). Assessment parameters were the vaccination effects on somatic 
cell count (SCC) and the effects of vaccine on the antibody isotype of milk. For this purpose, 
90 lactating cows of Holstein-Friesian were selected and divided into two groups. One group 
(n-44) served as vaccinated group and the second group (n-46) was the control group. First 
group received 5 mL of bacterin vaccine, 2 shots, 14 days apart. Milk samples were collected 
from individual quarters for bacterial culture before each shot and then collected monthly for 6 
months. For determining IgG1, IgG2, IgM, IgA, and SCC, composite samples of milk were col-
lected on days 0, 14, 28, 49, and 70. The authors did not observe any new IMI in any group and 
this was not different significantly between the groups (p > 0.05) of mammary quarter infection. 
The vaccine in herds having been reported with coagulase-negative staphylococcal prevalence 
(30%) and S. aureus prevalence (3%) in intra-mammary infection did not respond well to newer 
Staphylococcal infections. Another study has evaluated a multicomponent vaccine to eradicate 
staphylococcal biofilm infections [58]. Selected antigens including glucosaminidase (hypotheti-
cal conserved protein), an ABC transporter lipoprotein, and conserved lipoproteins have been 
found in previous studies to sustain and up-regulate expression in biofilms both in vitro and 
in vivo. For these antigens, the antibody was first used in a microscopic study to determine 
its expression in an in vitro biofilm. In biofilms, each of the four antigens exhibits heterolo-
gous production at different locations within a complex biofilm community. The four antigens 
were delivered simultaneously as a quadrivalent vaccine. As vaccine antigens were specific 
for biofilms, antibiotic treatments were also used to remove residual and non-adhered plank-
tonic cells. The results showed that the clinical and radiographic symptoms were reduced to 67 
and 82%, respectively, when the vaccine was given with vancomycin treated in biofilm rabbit 
models with chronic osteomyelitis. It was compared with animals infected or not treated with 
vancomycin. In contrast, only vaccination resulted in a modest and insignificant reduction.
Recently, Raza [47] evaluated the role of a bacterin toxoid prepared from a strong biofilm-
producing S. aureus in effective immunization of rabbits. The strong biofilm-producing S. aureus 
selected from 64 isolates of staphylococci was used to prepare bacterin toxoid, and aluminum 
hydroxide gel was added as an adjuvant. The vaccine was evaluated in rabbits by challenge 
protection assay and humoral immune response. The mortality rates in control and vaccinated 
groups were 80% and 10% at day 7 post-challenge and 100 and 20% at day 15 post-challenge, 
respectively. Serum antibody titer (GMT) was significantly higher (294.0) in vaccinated group 
as compared to the control group rabbits (2.63) at day 45. The results showed an increased 
antibody production in the vaccinated group that was capable of preventing establishment of 
new S. aureus infection in rabbits as compared to the control group. Based on the results of the 
present study, a short-term clinical trial was conducted in dairy cows and buffaloes which also 
showed effectiveness of vaccine as indicated by a significant difference in the prevalence and 
incidence of mastitis, high level of variation in the microbiological examination of milk, reduced 
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intra-mammary infections, and somatic cell counts between vaccinated and control groups of 
dairy cows and buffaloes.
3. Conclusions
Staphylococcus aureus from dairy animal origin has obtained more serious attention than 
that of human origin in terms of pathogenicity, strain variability, response to antibiotics, 
public health concern, and economic losses to the dairy industry. Apart from bovines, 
camel and caprine are noted with surged prevalence since last few years. Being contagious 
in nature, S. aureus has been found to be emerging due to the increase in the span of risk 
factors. As there is an increase in antibiotic resistance against S. aureus, the hope in the form 
of non-antibiotics like nanoparticles, plant derivatives, bacterial, and phage based-remedies 
exists. Vaccines, as a preventive strategy, have been implemented at local and commercial 
levels. The research is required for a comprehensive approach both at preventive and at 
therapeutic levels.
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